Global Urinary Tract Infection Testing Market Size study, by Type (Urethritis, Cystitis, Pyelonephritis), By End-Use (Reference Laboratories, General Practitioners, Urologists, Urgent Care, Urogynecologists, Hospital Laboratories, Hospital Emergency Depar

Global Urinary Tract Infection Testing Market Size study, by Type (Urethritis, Cystitis, Pyelonephritis), By End-Use (Reference Laboratories, General Practitioners, Urologists, Urgent Care, Urogynecologists, Hospital Laboratories, Hospital Emergency Departments, Others), and Regional Forecasts 2022-2028

Global Urinary Tract Infection Testing Market is valued at approximately XX in 2021 and is anticipated to grow with a healthy growth rate of more than xx% over the forecast period 2022-2028. Microbes are the primary cause of UTIs or urinary tract infections. Most of these organisms are bacteria. UTIs can also be brought on by viral and fungal infections, though. While UTIs can arise anywhere in the urinary tract, including the kidneys, uterus, bladder, and urethra, they typically affect the urethra and bladder. Due to factors like the rising disease burden, growing geriatric population, quick technological advancements, and high R&D investments by key players to introduce novel & innovative products, such as self-testing & rapid Point-of-Care (PoC) devices, the UTI testing market is experiencing growth. Urinary tract infections are a growing concern on a global scale. UTI affects one in five adult women at some point in their lives, according to studies. About 25 to 40 percent of American women between the ages of 20 and 40 have experienced a UTI. About 250,000 instances of pyelonephritis are recorded each year in the United States. It occurs in about 28/10,000 women between the ages of 18 and 19, and 7 percent of those instances necessitate hospitalisation. The introduction of portable handheld equipment, as well as the availability of at-home sample collection kits and self-testing kits for UTI testing, are among the factors that are likely to increase adoption. Healthy.io Ltd., for example, launched a home test kit in the United Kingdom in May 2020. Furthermore, point-of-care testing for UTIs will be a key growth area, with companies expected to increase investments. Furthermore, researchers are developing technologically advanced products for disease diagnosis, which are expected to be commercialised in space in the coming years. Engineers at the University of Bath created a test for UTIs using a smartphone camera in January 2020. They claim that it can detect E.coli in a urine sample in less than 25 minutes. False results from UTI testing, on the other hand, may stifle space growth. According to a CUTIC study, one out of every five patients will receive a false-positive result from a rapid test or dipstick test.

The key regions considered for the global Urinary Tract Infection Testing market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. In terms of value, North America dominated the overall urinary tract infection market. This can be attributed to improved reimbursement facilities as well as an increase in the adoption of novel diagnostic products as a result of increased awareness. Furthermore, during the forecast period, the Asia Pacific region is expected to have the highest CAGR. The rapid growth can be attributed to rising disease incidence rates and a large geriatric population.

Major market players included in this report are:
QIAGEN
Accelerate Diagnostics, Inc.
Bio-Rad Laboratories, Inc.
F. Hoffmann-La Roche Ltd.
Danaher Corporation
Siemens Healthcare GmbH
Randox Laboratories Ltd.
Thermo Fisher Scientific, Inc.
bioMérieux SA
T2 Biosystems, Inc.
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Type:
Urethritis
Cystitis
Pyelonephritis

By End-use:
General practitioners (GPs)
Urologists
Urogynecologists
Hospital Laboratories
Reference Laboratories
Hospital Emergency Departments
Urgent Care
Others

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019, 2020
Base year – 2021
Forecast period – 2022 to 2028

Target Audience of the Global Urinary Tract Infection Testing Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors

Companies Mentioned

QIAGEN
Accelerate Diagnostics, Inc.
Bio-Rad Laboratories, Inc.
F. Hoffmann-La Roche Ltd.
Danaher Corporation
Siemens Healthcare GmbH
Randox Laboratories Ltd.
Thermo Fisher Scientific, Inc.
bioMérieux SA
T2 Biosystems, Inc."